Why Shares of AVEO Hit the Brakes Today

Tivozanib, a cancer drug developed by AVEO Pharmaceuticals (NASDAQ: AVEO  ) and Astellas Pharma, is currently under FDA review. Shares of AVEO fell by 5% today after reporting its Q4 results and offering additional details from tivozanib's phase 3 clinical trial. This news has largely been expected by investors since last summer, and health care analyst Max Macaluso breaks down what happened today in this video.

Is this a cancer-focused biotech to watch?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2253563, ~/Articles/ArticleHandler.aspx, 11/27/2014 12:48:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement